Tharimmune Faces Delisting Concerns

Ticker: CNTN · Form: 8-K · Filed: Apr 4, 2025 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateApr 4, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

THARIMUNE IS ON THE EDGE OF BEING DELISTED - MAJOR RED FLAG!

AI Summary

Tharimmune, Inc. filed an 8-K on April 1, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Hillstream BioPharma Inc., is incorporated in Delaware and has its principal executive offices in Bridgewater, NJ.

Why It Matters

This filing indicates potential issues with Tharimmune's continued listing on an exchange, which could significantly impact its stock value and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading status and overall financial health.

Key Numbers

Key Players & Entities

FAQ

What specific listing rule or standard has Tharimmune, Inc. failed to satisfy?

The filing does not specify the exact rule or standard that Tharimmune, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule has been issued.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is April 1, 2025.

What was Tharimmune, Inc.'s former company name?

Tharimmune, Inc.'s former company name was Hillstream BioPharma Inc.

In which state is Tharimmune, Inc. incorporated?

Tharimmune, Inc. is incorporated in Delaware.

What is the address of Tharimmune, Inc.'s principal executive offices?

The address of Tharimmune, Inc.'s principal executive offices is 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 regarding Tharimmune, Inc. (CNTN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing